Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical markets. With over 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to its customers' most challenging questions.
Agilent brings the power of precision medicine to customers, partners, and patients. Agilent is a partner of choice to pharmaceutical and biotech companies producing innovative diagnostics and therapeutics for the benefit of patients around the world.
Natera has developed Signatera, a personalized ctDNA test for molecular residual disease (MRD) detection and recurrence monitoring in patients previously diagnosed with cancer. Signatera's tumor-informed assay is optimized to detect low levels of ctDNA, with high accuracy in identifying MRD and recurrence with longer lead times. Signatera has been clinically validated in multiple cancer types including colorectal, non-small cell lung, breast, and bladder cancers. The test is available for clinical and research use, and has been designated by the FDA as a Breakthrough Device. Look deeper at natera.com/oncology
Proteome Sciences is a CRO specializing in the analysis of proteins detected by Mass Spectrometry. We offer various Discovery and Targeted Services to characterize proteins and their associated post-translational modifications. By using LC-MS2, SysQuant®, and TMTcalibratorTM methodologies we can detect up to 8,000 of proteins/sample. With our proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up- or down-regulated with disease progression or drug treatment.
Owlstone Medical’s mission is to save 100,000 lives and $1.5 billion in healthcare costs by realizing the potential of breath biomarkers for early detection and precision medicine through Breath Biopsy®. Breath Biopsy provides reliable solutions for the collection and analysis of volatile organic compounds (VOCs) produced through metabolic processes or as a result of interaction with external factors such as diet or medication. Changes to exhaled VOCs can be associated with a range of disease conditions and environmental exposures.
NeoGenomics is an industry-leading cancer diagnostics and pharma services company. We enable advanced oncology patient care leveraging the most extensive diagnostic solid tumor and hematological test menus, sub-specialized pathology, and expertise in biomarker development. We partner closely with our pharma and research clients to meet program objectives and delivery from biomarker discovery through CDx validation and commercialization.
Sysmex America is lighting the way to better health with diagnostic solutions that transform the future of healthcare and contribute to healthier lives. Its innovative hematology, urinalysis and flow cytometry testing technology is reshaping the world of diagnostics across the U.S., Canada and Latin America. As a trusted global leader, Sysmex offers diagnostics that equip patients and the health care professionals who treat them with the information needed to make decisions with confidence.
PHC Holdings Corporation is a global healthcare company with its products and services used in more than 125 countries. Subsidiaries include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia and LSI Medience Corporation. The company develops, manufactures, sells and services medical equipment and solutions across the diabetes management, diagnostics, life sciences and healthcare services. Epredia is a global leader in the anatomical pathology field, providing comprehensive solutions for precision cancer diagnostics. URL: www.phchd.com
Predicine is a molecular insights company committed to advancing biomarker-driven precision medicine. It has developed a breakthrough cell-free DNA and cell-free RNA based liquid biopsy technology for non-invasive cancer profiling, disease monitoring, assessing MRD, and early cancer detection. Predicine partners with leading biopharma companies and hospitals to support global clinical trials and personalized cancer care.
Arima Genomics is a biotechnology company based in San Diego, California. Our products enable companies to classify disease more accurately, identify new biomarkers and therapeutic targets, and characterize novel mechanisms driving known targets. Our mission is to accelerate the understanding of genome sequence and structure toward improved diagnostics, more effective therapeutic development, and ultimately better treatments for patients. For additional information, please visit www.arimagenomics.com.